AUTO5 / Autolus - LARVOL DELTA

Autolus Therapeutics announces publication in Nature Communications (GlobeNewswire) - "Autolus Therapeutics plc...today announces a publication in Nature Communications...AUTO4 may allow for treatment of TRBC1 T cell lymphomas but should preserve the normal TRBC2 T cell compartment, preventing immunosuppression...In this publication, the research team at Autolus first describe the structural basis for selective AUTO4 CAR recognition of TRBC1. This structure shows that some amino acid residues stabilize the interaction with the TCR generally, while others result in selectivity. By exploiting this structure, the research team used in silico design and phage display to flip selectivity of the AUTO4 binder from TRBC1 to TRBC2 to generate AUTO5, a TRBC2-specific CAR T cell therapeutic."

Preclinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress (GlobeNewswire) - "Key Anticipated Clinical Milestones: Non-clinical data and initial data from the AUTO1/22 CARPALL extension trial in pediatric ALL expected at ASH in December 2021; Updates on the AUTO4 Phase 1 trial in TRBC1+ Peripheral TCL expected in H1 2022; Phase 1 trials are expected to be initiated in Q4 2021 with AUTO8 in Multiple Myeloma; Phase 1 trials are expected to be initiated in H1 2022 with AUTO6NG in solid tumors and AUTO5 in TRBC2+ Peripheral TCL."

Clinical data • New P1 trial • Childhood B Acute Lymphoblastic Leukemia • Hematological Malignancies • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma

Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress (GlobeNewswire) - “Updates on the obe-cel Phase 1 trial, CAROUSEL, in Primary CNS Lymphoma in Q1 2022; Updates on the AUTO4 Phase 1 trial in TRBC1+ Peripheral TCL in H1 2022; Phase 1 trials are expected to be initiated in H1 2022 with AUTO6NG in solid tumors and AUTO5 in TRBC2+ Peripheral TCL; First exploratory allogeneic development candidate expected to enter the clinic in 2021.”

New P1 trial • New trial • P1 data • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress (GlobeNewswire) - "Key Upcoming Clinical Milestones: AUTO1 updates in 2021 on ALLCAR19 in patients with r/r B-NHL and longer term follow up of the fully enrolled r/r aALL cohort. AUTO1 - Currently enrolling a potentially pivotal Phase 1b/2 clinical trial (FELIX) in r/r adult ALL patients with data expected in 2022. Updates on Phase 1 programs AUTO1/22 in pediatric ALL, as well as AUTO4 in TRBC1+ Peripheral TCL, in 2021. Phase 1 trials are expected to be initiated in 2021 with AUTO1 in Primary CNS Lymphoma, AUTO5 in TRBC2+ Peripheral TCL, AUTO6NG in Neuroblastoma, and AUTO8 in Multiple Myeloma."

New trial • P1/2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Multiple Myeloma • Neuroblastoma • Non-Hodgkin’s Lymphoma • Oncology

Autolus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress (GlobeNewswire) - “AUTO7 in prostate cancer: Autolus plans to progress AUTO7 into the clinic in H1 2022...AUTO1 updates in 2021 on ALLCAR19 in patients with r/r B-NHL and longer term follow up of the fully enrolled r/r aALL cohort; AUTO1 - Currently enrolling Phase 1b/2 pivotal study (FELIX) in r/r adult ALL patients with data expected in 2022; Updates on Phase 1 programs AUTO1/22 in pediatric ALL, as well as AUTO4 in TRBC1+ Peripheral TCL, in 2021; Phase 1 trials are expected to be initiated in 2021 with AUTO1 in Primary CNS Lymphoma, AUTO5 in TRBC2+ Peripheral TCL, AUTO6NG in Neuroblastoma, and AUTO8 in Multiple Myeloma; First exploratory allogeneic program expected to enter the clinic in H1 2021.”

New P1 trial • New trial • P1 data • P1/2 data • Acute Lymphocytic Leukemia • Genito-urinary Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Multiple Myeloma • Neuroblastoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Prostate Cancer • Small Cell Lung Cancer